Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Mirati therapeutics, inc. save search
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.04%
H: 0.35%
C: -0.53%
lung cancer cell results
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Published: 2023-09-10 (Crawled : 04:20) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
| Email alert
Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
lung conference world cancer response study
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.5%
H: 1.29%
C: -1.02%
lung conference world cancer results study
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -14.97%
H: 11.97%
C: 8.9%
lung review update cancer cell treatment therapeutics
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
Published: 2022-12-21 (Crawled : 23:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 2.98%
H: 2.99%
C: 2.14%
fda designation therapy cancer phase 2b
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
Published: 2022-12-13 (Crawled : 11:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 2.13%
H: 0.3%
C: -2.2%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 2.13%
H: 0.3%
C: -2.2%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.16%
H: 1.41%
C: 0.19%
fda lung diagnostic approval cancer
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2022-12-12 (Crawled : 00:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.16%
H: 1.41%
C: 0.19%
krasg12 treatment fda lung approval therapeutics cancer
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Published: 2022-12-05 (Crawled : 00:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -16.68%
H: 3.91%
C: -7.45%
lung therapeutics results cancer
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Published: 2022-12-05 (Crawled : 00:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.74%
H: 2.03%
C: 0.06%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -16.68%
H: 3.91%
C: -7.45%
lung therapeutics results cancer
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
AADI | $1.835 1.94% 1.91% 140K
|
Manufacturing
|
| O: 3.7%
H: 0.0%
C: -7.64%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.14%
H: 5.61%
C: 5.46%
lung therapeutics tumors bioscience cancer
Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer
Published: 2022-09-07 (Crawled : 23:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.57%
H: 8.57%
C: 5.65%
therapeutics results cancer
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
krasg12 system cancer
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
VSTM | $9.86 -3.62% -3.75% 150K
|
Health Technology
|
| O: 3.05%
H: 0.74%
C: -9.63%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
vs-6766 cancer defactinib ovarian cancer
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
Published: 2022-05-19 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 4.19%
H: 2.67%
C: 2.0%
krasg12 treatment application therapeutics authorization cancer
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
Published: 2022-04-27 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.21%
H: 0.88%
C: -2.15%
krasg12 research therapeutics asco cancer
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.42%
H: 5.52%
C: 4.35%
krasg12 new drug treatment fda application drug therapeutics cel food lung cancer cancer fda acceptance
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
Published: 2022-01-21 (Crawled : 15:30) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
krasg12 gastrointestinal therapeutics test positive cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.